Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?

International Journal of Gynecological Cancer

Volumn 23, Issue 3, 2013, Pages 431-436

  Powell, C Bethan ^a   Littell, Ramey ^a   Hoodfar, Elizabeth ^b   Sinclair, Fiona ^c   Pressman, Alice ^c  

^a Gynecology Oncology Program   (United States)

^b Northern California Regional Genetics Program   (United States)

^c DIVISION OF RESEARCH   (United States)

Author keywords

BRCA testing; Breast cancer; Genetic referral; Ovarian cancer

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVARY CANCER; PATIENT REFERRAL; PERITONEUM CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERINE TUBE CARCINOMA;

ADULT; BREAST NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GENETIC COUNSELING; GENETIC TESTING; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PILOT PROJECTS; REFERRAL AND CONSULTATION;

EID: 84876223173     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318280f2b4     Document Type: Article

References (22)

1. Narod S, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;57:957-958.
2. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000;83:1301-1308.
3. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.
4. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409-1415.
5. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16:2417-2425.
6. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145-158.
7. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997;278:1242-1250.
8. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107:159-162.
9. ACOG. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;113:957-966. Myriad Laboratories Annual Report, 2008.
10. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-975.
11. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:1055-1062.
12. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159-164.
13. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006;24:4642-4660.
14. Boyd J, SonodaY, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-2265.
15. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20:463-466.
16. Pal T, Permuth-Wey J, Kapoor R, et al. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer. 2007;6:113-119.
17. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187-2195.
18. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996;335:1413-1416.
19. Audeh MW, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet. 2010;376;245-251.
20. National Comprehensive Cancer Network. Genetic/familial high-risk assessment of breastandovarianclinicalpracticeguidelinesinoncology. Available at:http://www.nccn.org/professionals/physician-gls/PDF. Accessed 1 December 2012.
21. Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: Missed opportunities. Obstet Gynecol. 2010;115:945-952.
22. Metcalfe KA, Fan I, McLaughlin J, et al. Uptake of clinical genetic testing for ovarian cancer in Ontario: A population based study. Gynecol Oncol. 2009;112:68-72.